Non-alcohol fatty liver disease in Asia: Prevention and planning
- PMID: 26167252
- PMCID: PMC4491908
- DOI: 10.4254/wjh.v7.i13.1788
Non-alcohol fatty liver disease in Asia: Prevention and planning
Abstract
Aim: To review all of epidemiological aspects of non-alcoholic fatty liver disease (NAFLD) and also prevent this disease is examined.
Methods: We conducted a systematic review according to the PRISMA guidelines. All searches for writing this review is based on the papers was found in PubMed (MEDLINE), Cochrane database and Scopus in August and September 2014 for topic of NAFLD in Asia and the way of prevention of this disease, with no language limitations. All relevant articles were accessed in full text and all relevant materials was evaluated and reviewed.
Results: NAFLD is the most common liver disorder in worldwide, with an estimated with 20%-30% prevalence in Western countries and 2%-4% worldwide. The prevalence of NAFLD in Asia, depending on location (urban vs rural), gender, ethnicity, and age is variable between 15%-20%. According to the many studies in the world, the relationship between NAFLD, obesity, diabetes mellitus, and metabolic syndrome (MS) is quiet obvious. Prevalence of NAFLD in Asian countries seems to be lower than the Western countries but, it has increased recently due to the rise of obesity, type 2 diabetes and MS in this region. One of the main reasons for the increase in obesity, diabetes and MS in Asia is a lifestyle change and industrialization. Today, NAFLD is recognized as a major chronic liver disease in Asia. Therefore, prevention of this disease in Asian countries is very important and the best strategy for prevention and control of NAFLD is lifestyle modifications. Lifestyle modification programs are typically designed to change bad eating habits and increase physical activity that is associated with clinically significant improvements in obesity, type 2 diabetes and MS.
Conclusion: Prevention of NAFLD is very important in Asian countries particularly in Arab countries because of high prevalence of obesity, diabetes and MS.
Keywords: Asian countries; Metabolic risk factors; Non-alcoholic fatty liver disease; Prevention.
Similar articles
-
Hepatocellular carcinoma in Asia: Prevention strategy and planning.World J Hepatol. 2015 Jun 28;7(12):1708-17. doi: 10.4254/wjh.v7.i12.1708. World J Hepatol. 2015. PMID: 26140091 Free PMC article.
-
Non-alcoholic fatty liver disease in the Asia-Pacific region: definitions and overview of proposed guidelines.J Gastroenterol Hepatol. 2007 Jun;22(6):778-87. doi: 10.1111/j.1440-1746.2007.05001.x. J Gastroenterol Hepatol. 2007. PMID: 17565630
-
New trends on obesity and NAFLD in Asia.J Hepatol. 2017 Oct;67(4):862-873. doi: 10.1016/j.jhep.2017.06.003. Epub 2017 Jun 19. J Hepatol. 2017. PMID: 28642059 Review.
-
What are the risk factors and settings for non-alcoholic fatty liver disease in Asia-Pacific?J Gastroenterol Hepatol. 2007 Jun;22(6):794-800. doi: 10.1111/j.1440-1746.2007.04952.x. Epub 2007 May 13. J Gastroenterol Hepatol. 2007. PMID: 17498218
-
Nonalcoholic fatty liver disease in Asia: emerging perspectives.J Gastroenterol. 2017 Feb;52(2):164-174. doi: 10.1007/s00535-016-1264-3. Epub 2016 Sep 16. J Gastroenterol. 2017. PMID: 27637587 Review.
Cited by
-
Chemical Constituents with Anti-Lipid Droplet Accumulation and Anti-Inflammatory Activity from Elaeagnus glabra.Plants (Basel). 2023 Aug 14;12(16):2943. doi: 10.3390/plants12162943. Plants (Basel). 2023. PMID: 37631155 Free PMC article.
-
Reparative Effects of Astaxanthin-Hyaluronan Nanoaggregates against Retrorsine-CCl₄-Induced Liver Fibrosis and Necrosis.Molecules. 2018 Mar 22;23(4):726. doi: 10.3390/molecules23040726. Molecules. 2018. PMID: 29565318 Free PMC article.
-
Fatty liver index vs waist circumference for predicting non-alcoholic fatty liver disease.World J Gastroenterol. 2016 Mar 14;22(10):3023-30. doi: 10.3748/wjg.v22.i10.3023. World J Gastroenterol. 2016. PMID: 26973398 Free PMC article.
-
The Lifestyle Characteristics in Non-Alcoholic Fatty Liver Disease in the PERSIAN Guilan Cohort Study.Open Access Maced J Med Sci. 2019 Sep 14;7(19):3313-3318. doi: 10.3889/oamjms.2019.647. eCollection 2019 Oct 15. Open Access Maced J Med Sci. 2019. PMID: 31949537 Free PMC article.
-
Vildagliptin ameliorates biochemical, metabolic and fatty changes associated with non alcoholic fatty liver disease.Pak J Med Sci. 2016 Nov-Dec;32(6):1396-1401. doi: 10.12669/pjms.326.11133. Pak J Med Sci. 2016. PMID: 28083033 Free PMC article.
References
-
- Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Dig Dis. 2010;28:155–161. - PubMed
-
- Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006;43:S99–S112. - PubMed
-
- Suzuki A, Angulo P, Lymp J, St Sauver J, Muto A, Okada T, Lindor K. Chronological development of elevated aminotransferases in a nonalcoholic population. Hepatology. 2005;41:64–71. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials